LAB TO ASSESS AIDS INDUCED MUCOSAL IMMUNE RESPONSES

由于获得性免疫缺陷综合症（艾滋病）的流行， 继续增长，开发有效疫苗的重要性， 预防感染人类免疫缺陷病毒（HIV）， 艾滋病的发展越来越重要。 据估计 80%的艾滋病病毒通过粘膜表面的性传播传播 世界范围内。 直到最近，在第一阶段试验中的候选艾滋病疫苗 不是专门设计用于诱导粘膜免疫， 还没有研究它们在诱导这种反应方面的有效性。 然而，新的候选艾滋病疫苗，包括活载体疫苗和 用新的佐剂或递送系统工程化的那些， 粘膜免疫反应，可用于I/II期试验 临床试验 评估对HIV的免疫应答的方法 在发生HIV传播的粘膜部位接种疫苗。 NIAID艾滋病司目前支持五种艾滋病疫苗， 评价股合同。 AVEU一家在约翰霍普金斯大学 大学，巴尔的摩，MD（N 01-AI-05061），圣路易斯大学，圣路易斯。 密苏里州路易斯（N 01-AI-05064），罗切斯特大学，纽约州罗切斯特（N 01-AI- 05063），华盛顿大学，西雅图，WA（N 01-AI-05065）和 范德比尔特大学，纳什维尔，田纳西州（N 01-AI-05062）。 中央 免疫学实验室合同，目前由杜克大学持有（N 01- AI-15106），为AVEU提供集中、统一的 志愿者的选择性抗HIV抗体和细胞免疫应答 在这些试验中。 但是，这些评估不包括评价 抗HIV粘膜免疫反应的影响。 因此，我们认为， 该合同将建立粘液免疫学实验室， 调整、标准化和执行体液和细胞粘膜检测 原型免疫诱导的志愿者免疫应答 艾滋病疫苗的I/II期临床试验。

As the pandemic of the Acquired Immunodeficiency Syndrome (AIDS) continues to grow, the importance of developing effective vaccines to prevent infection with Human Immunodeficiency Virus (HIV) and the development of AIDS assumes increasing importance. It is estimated that HIV is spread by sexual transmission at mucosal surfaces in 80% of cases world-wide. Until recently, candidate AIDS vaccines in Phase I trials have either not been specifically designed to induce mucosal immunity or have not been studied for their effectiveness in inducing such responses. However, new candidate AIDS vaccines, including live vector vaccines and those engineered with novel adjuvant or delivery systems for inducing a mucosal immune response, are becoming available for testing in Phase I/II Clinical Trials. Methodology for evaluating the immune responses to HIV vaccines at mucosal sites where transmission of HIV occurs. The Division of AIDS, NIAID, currently supports five AIDS Vaccine Evaluation Unit (AVEU) contracts. The AVEUs are at Johns Hopkins University, Baltimore, MD (N01-AI-05061), St. Louis University, St. Louis, MO (N01-AI-05064), University of Rochester, Rochester, NY (N01-AI- 05063), University of Washington, Seattle, WA (N01-AI-05065) and Vanderbilt University, Nashville, TN (N01-AI-05062). A Central Immunology Laboratory contract, currently held by Duke University (N01- AI-15106), serves the AVEUs providing centralized, uniform assessment of selected anti-HIV antibody and cellular immune responses of volunteers in these trials. However, these assessments do not include evaluation of the anti-HIV mucosal immune responses in the vaccinees. Therefore, this contract will establish the Mucosal Immunology Laboratory which will adapt, standardize, and perform assays for humoral and cellular mucosal immune responses induced in volunteers by immunization with prototype AIDS vaccines in Phase I/II Clinical Trials.